RSS Immix Biopharma Reports Positive Early Results From NEXICART-2 Trial Of NXC-201 In AL Amyloidosis

Currently reading:
 RSS Immix Biopharma Reports Positive Early Results From NEXICART-2 Trial Of NXC-201 In AL Amyloidosis

Status
Not open for further replies.

Crax Bot

Staff member
Administrator
Amateur
LV
0
Joined
Nov 5, 2021
Threads
6,604
Likes
1,919
Credits
32,844©
Cash
0$
Immix Biopharma, Inc. (IMMX), a biopharmaceutical company at the clinical stage, reported promising early findings from the NEXICART-2 U.S. trial of NXC-201 targeted at treating relapsed/refractory Light Chain (AL) Amyloidosis. The NEXICART-2 is the only CAR-T therapy clinical trial currently underway in the U.S. for AL Amyloidosis.

The study's primary objective is to assess the efficacy of NXC-201 in patients who haven't responded to previous treatments, provided they have preserved cardiac function. Immix Biopharma remains optimistic that these initial results support its strategy, with an expectation of future complete treatment responders.

Notably, all four patients underwent normalization of their disease markers within 30 days post-treatment with NXC-201. Of these, two have been identified as complete responders, while the remaining two recorded bone marrow minimal residual disease (MRD) negativity.

As of the November 14, 2024 cutoff, all patients have maintained their response status. The significance of these results is heightened given the patients' median of four previously failed treatment regimens before receiving NXC-201.

Highlighted results include:

- Two patients achieving complete responder status and two others exhibiting MRD negativity.

- Normalization of disease indicators for all patients, including decreased free light chains (FLC) and M-spike.

- Absence of immune effector cell-associated neurotoxicity syndrome (ICANS) or severe cytokine release syndrome (CRS) in participants. Mild CRS, classified as Grade 1 and 2, was observed in two individuals and was effectively managed with tocilizumab.

- The treatment was well-received overall, with no significant hematologic or other treatment-related adverse effects.

Immix Biopharma remains committed to enrolling more patients in the study and plans to offer an update during the first half of 2025. Interim data releases are expected in Q2 or Q3 of 2025, while final topline results are anticipated by Q2 or Q3 of 2026.

A conference call to discuss these topline data insights will take place today, December 19, 2024, at 11:00 AM ET. Currently, IMMX shares are trading at $2.21, reflecting a 5.30% increase.

The material has been provided by InstaForex Company - www.instaforex.com
 
Status
Not open for further replies.
Tips

Similar threads

Top Bottom